A computational drug-repurposing strategy identified auranofin, the oral gold-based compound approved in 1985 for rheumatoid arthritis, as a potent inhibitor of atherosclerotic plaque progression and arterial wall inflammation in animals. The work also linked the compound’s predicted effects to reduced cardiovascular risk in humans. The approach used disease-specific gene regulatory networks to pinpoint mechanistic associations and potential therapeutic vulnerabilities. The study’s output frames auranofin as acting against plaque development and inflammatory processes relevant to atherosclerosis biology. For cardiovascular and translational biopharma teams, the report adds another repurposing candidate to the growing portfolio of pathway-driven repositioning efforts—particularly where existing safety history can accelerate preclinical-to-clinical planning.